- Home
- RFI vs ORGO Comparison
RFI vs ORGO Comparison
Compare RFI & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- ORGO
- Stock Information
- Founded
- RFI 1992
- ORGO 1985
- Country
- RFI United States
- ORGO United States
- Employees
- RFI N/A
- ORGO N/A
- Industry
- RFI Investment Managers
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- ORGO Health Care
- Exchange
- RFI Nasdaq
- ORGO Nasdaq
- Market Cap
- RFI 323.2M
- ORGO 384.4M
- IPO Year
- RFI N/A
- ORGO N/A
- Fundamental
- Price
- RFI $12.06
- ORGO $3.46
- Analyst Decision
- RFI
- ORGO Buy
- Analyst Count
- RFI 0
- ORGO 2
- Target Price
- RFI N/A
- ORGO $5.50
- AVG Volume (30 Days)
- RFI 69.8K
- ORGO 911.8K
- Earning Date
- RFI 01-01-0001
- ORGO 08-07-2025
- Dividend Yield
- RFI 8.25%
- ORGO N/A
- EPS Growth
- RFI N/A
- ORGO N/A
- EPS
- RFI N/A
- ORGO N/A
- Revenue
- RFI N/A
- ORGO $458,760,000.00
- Revenue This Year
- RFI N/A
- ORGO $2.62
- Revenue Next Year
- RFI N/A
- ORGO $12.46
- P/E Ratio
- RFI N/A
- ORGO N/A
- Revenue Growth
- RFI N/A
- ORGO 5.35
- 52 Week Low
- RFI $9.62
- ORGO $2.28
- 52 Week High
- RFI $12.52
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- RFI 54.20
- ORGO 54.42
- Support Level
- RFI $11.79
- ORGO $3.13
- Resistance Level
- RFI $12.07
- ORGO $3.36
- Average True Range (ATR)
- RFI 0.14
- ORGO 0.21
- MACD
- RFI -0.01
- ORGO 0.08
- Stochastic Oscillator
- RFI 74.17
- ORGO 74.36
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.